This segment focuses on the research, development, and commercialization of Chimeric Antigen Receptor (CAR) T-cell therapies for the treatment of hematological malignancies, particularly multiple myeloma. The core technology involves genetically engineering a patient's own T-cells to recognize and attack cancer cells. Research and development activities include clinical trials, process optimization, and manufacturing scale-up. The primary product in this segment is Abecma, a CAR T-cell therapy for multiple myeloma. This segment addresses the unmet medical needs of patients with relapsed or refractory multiple myeloma, offering a potentially curative treatment option. Market positioning is based on innovation and partnerships with major pharmaceutical companies. Future opportunities include expanding the application of CAR T-cell therapy to other cancers and improving the efficacy and safety of existing treatments. Regulatory and clinical aspects involve navigating FDA approval processes and conducting post-market surveillance. Partnerships with Bristol Myers Squibb are crucial for commercialization and global reach.

This segment encompasses all research and development activities related to the company's pipeline of oncology cell therapies. This includes early-stage discovery, preclinical studies, clinical trial management, and translational research. The company utilizes advanced technologies such as gene editing, viral vector design, and cell manufacturing processes to develop novel therapies. The therapeutic focus is primarily on hematological malignancies and solid tumors. The segment aims to improve patient outcomes by developing innovative treatments with improved efficacy and safety profiles. Market positioning is based on scientific innovation and the ability to translate research into clinical applications. Future opportunities include expanding the pipeline, exploring new targets, and leveraging partnerships to accelerate development. Regulatory aspects involve navigating the complex landscape of clinical trial regulations and seeking approvals from regulatory bodies. The segment collaborates with academic institutions, research organizations, and pharmaceutical companies to advance its research programs.